Bluesky Facebook Reddit Email

Predicting relapses in patients with autoimmune vascular disease

05.23.18 | Wiley

SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.

Patients with an autoimmune disorder called antineutrophil cytoplasmic antibody-associated vasculitis produce antibodies that damage blood vessels in the body. In some cases, patients' antibodies target a protein called myeloperoxidase. New research published in Arthritis & Rheumatology indicates that for patients in remission, reappearance of antibodies against myeloperoxidase is a sign that patients will experience a relapse of their disease.

The findings suggest that patients should undergo routine monitoring of antibodies against myeloperoxidase.

"Our results could be helpful in daily clinical practice related to antineutrophil cytoplasmic antibody-associated vasculitis," said co-author Dr. Ken-Ei Sada, of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, in Japan.

###

Arthritis & Rheumatology

10.1002/art.40538

Keywords

Article Information

Contact Information

How to Cite This Article

APA:
Wiley. (2018, May 23). Predicting relapses in patients with autoimmune vascular disease. Brightsurf News. https://www.brightsurf.com/news/LP2O6YML/predicting-relapses-in-patients-with-autoimmune-vascular-disease.html
MLA:
"Predicting relapses in patients with autoimmune vascular disease." Brightsurf News, May. 23 2018, https://www.brightsurf.com/news/LP2O6YML/predicting-relapses-in-patients-with-autoimmune-vascular-disease.html.